Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Reeder
Craig B
CB
Reece
Donna E
DE
Kukreti
Vishal
V
Chen
Christine
C
Trudel
Suzanne
S
Laumann
Kristina
K
Hentz
Joseph
J
Pirooz
Nicholas A
NA
Piza
Jesus G
JG
Tiedemann
Rodger
R
Mikhael
Joseph R
JR
Bergsagel
Peter L
PL
Leis
Jose F
JF
Fonseca
Rafael
R
Stewart
Alexander K
AK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide